Prenetics Global Limited (NASDAQ:PRE) Short Interest Up 19.8% in March

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 39,300 shares, an increase of 19.8% from the February 28th total of 32,800 shares. Based on an average trading volume of 12,400 shares, the short-interest ratio is currently 3.2 days. Approximately 0.5% of the company’s stock are sold short.

Prenetics Global Stock Performance

Shares of NASDAQ:PRE traded down $0.02 during trading on Wednesday, reaching $3.93. 10,037 shares of the stock traded hands, compared to its average volume of 35,633. Prenetics Global has a 52-week low of $2.85 and a 52-week high of $7.84. The stock has a market cap of $47.97 million, a P/E ratio of -0.98 and a beta of -0.31. The stock has a 50-day moving average of $4.91 and a two-hundred day moving average of $4.92.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned about 0.10% of Prenetics Global as of its most recent filing with the SEC. Institutional investors own 25.01% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 price target on shares of Prenetics Global in a research note on Thursday, January 16th.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.